Hypocellular acute leukemia

Robert B. Howe; Clara D. Bloomfield; Robert W. McKenna

doi:10.1016/0002-9343(82)90494-6

Hypocellular acute leukemia

Robert B. Howe, Clara D. Bloomfield, Robert W. McKenna

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

We examined the clinical features and therapeutic response of a group of patients with acute leukemia and hypocellular bone marrow. Therapists have generally avoided, delayed or modified therapy because of hypocellularity. We demonstrated not only that aggressive therapy is possible, but also that the remission rate is high (complete remission = 73 percent) and survival prolonged (x̄ > 40 months).

Original language	English (US)
Pages (from-to)	391-395
Number of pages	5
Journal	The American Journal of Medicine
Volume	72
Issue number	3
DOIs	https://doi.org/10.1016/0002-9343(82)90494-6
State	Published - Mar 1982

Bibliographical note

Funding Information:
From the Sections of Hematology and Medical Oncology, Department of Medicine and the Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota. This work was supported in part by the Ernest Johnson Memorial Leukemia Research Fund, NHLB Training Grant #5T32 HL07062, the Masonic Hospital Foundation and the Minnesota Medical Foundation. Reprint requests should be addressed to Dr. Robert Howe, University of Minnesota Hospitals, Box 480 Mayo Memo&l Building, Minneapolis, Minnesota 55455. Manuscript accepted October 6, 196 1.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/0002-9343(82)90494-6

OpenUrl availability

Full text

Cite this

@article{0479fb6624ec4bd3ac9165f889a876a4,

title = "Hypocellular acute leukemia",

abstract = "We examined the clinical features and therapeutic response of a group of patients with acute leukemia and hypocellular bone marrow. Therapists have generally avoided, delayed or modified therapy because of hypocellularity. We demonstrated not only that aggressive therapy is possible, but also that the remission rate is high (complete remission = 73 percent) and survival prolonged ({\=x} > 40 months).",

author = "Howe, {Robert B.} and Bloomfield, {Clara D.} and McKenna, {Robert W.}",

note = "Funding Information: From the Sections of Hematology and Medical Oncology, Department of Medicine and the Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota. This work was supported in part by the Ernest Johnson Memorial Leukemia Research Fund, NHLB Training Grant #5T32 HL07062, the Masonic Hospital Foundation and the Minnesota Medical Foundation. Reprint requests should be addressed to Dr. Robert Howe, University of Minnesota Hospitals, Box 480 Mayo Memo&l Building, Minneapolis, Minnesota 55455. Manuscript accepted October 6, 196 1.",

year = "1982",

month = mar,

doi = "10.1016/0002-9343(82)90494-6",

language = "English (US)",

volume = "72",

pages = "391--395",

journal = "The American Journal of Medicine",

issn = "0002-9343",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Hypocellular acute leukemia

AU - Howe, Robert B.

AU - Bloomfield, Clara D.

AU - McKenna, Robert W.

N1 - Funding Information: From the Sections of Hematology and Medical Oncology, Department of Medicine and the Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota. This work was supported in part by the Ernest Johnson Memorial Leukemia Research Fund, NHLB Training Grant #5T32 HL07062, the Masonic Hospital Foundation and the Minnesota Medical Foundation. Reprint requests should be addressed to Dr. Robert Howe, University of Minnesota Hospitals, Box 480 Mayo Memo&l Building, Minneapolis, Minnesota 55455. Manuscript accepted October 6, 196 1.

PY - 1982/3

Y1 - 1982/3

N2 - We examined the clinical features and therapeutic response of a group of patients with acute leukemia and hypocellular bone marrow. Therapists have generally avoided, delayed or modified therapy because of hypocellularity. We demonstrated not only that aggressive therapy is possible, but also that the remission rate is high (complete remission = 73 percent) and survival prolonged (x̄ > 40 months).

AB - We examined the clinical features and therapeutic response of a group of patients with acute leukemia and hypocellular bone marrow. Therapists have generally avoided, delayed or modified therapy because of hypocellularity. We demonstrated not only that aggressive therapy is possible, but also that the remission rate is high (complete remission = 73 percent) and survival prolonged (x̄ > 40 months).

UR - http://www.scopus.com/inward/record.url?scp=0020077525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020077525&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(82)90494-6

DO - 10.1016/0002-9343(82)90494-6

M3 - Article

C2 - 6949478

AN - SCOPUS:0020077525

SN - 0002-9343

VL - 72

SP - 391

EP - 395

JO - The American Journal of Medicine

JF - The American Journal of Medicine

IS - 3

ER -

Hypocellular acute leukemia

Abstract

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this